AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca PLC (NASDAQ:AZN ) Q3 2023 Earnings Conference Call November 9, 2023 9:00 AM ET Corporate Participants Andy Barnett - Head, Investor Relations Pascal Soriot - Chief Executive Officer Aradhana Sarin - Chief Financial Officer David Fredrickson - EVP, Oncology Business Susan Galbraith - EVP, Oncology R&D Ruud Dobber - EVP, BioPharmaceuticals Business Sharon Barr - EVP, BioPharmaceuticals R&D Marc Dunoyer - Chief Executive Officer, Alexion Conference Call Participants Steve Scala - Cowen Gonzalo Artiach - ABG Andrew Baum - Citi Sachin Jain - Bank of America Tim Anderson - Bernstein Emily Field - Barclays James Gordon - JPMorgan Mattias Häggblom - Handelsbanken Mark Purcell - Morgan Stanley Eric Le Berrigaud - Stifel Richard Parkes - BNP Christopher Uhde - SEB Simon Baker - Redburn Luisa Hector - Berenberg Emmanuel Papadakis - Deutsche Bank Peter Welford - Jefferies Operator Good morning to those joining from the U.S. Good afternoon to those in the U.K. and Central Europe and good evening to those listening in Asia. Welcome, ladies and gentlemen to AstraZeneca's Nine Months and Q3 Results 2023 Conference Call and Webinar for Investors and Analysts.

AstraZeneca PLC (AZN) Q3 2023 Earnings Call Transcript

AstraZeneca (AZN) announced a deal for an experimental weight-loss pill and raised its guidance on higher demand for its cancer treatments.

AstraZeneca Strikes a Deal for an Experimental Weight-Loss Drug and Boosts Its Guidance

A UK father and a widower have filed lawsuits against AstraZeneca PLC (LSE:AZN), claiming that the Oxford-AstraZeneca Covid-19 vaccine was defective and caused blood clots and brain injuries to their loved ones, according to reports.   Two court cases were filed by relatives of patients of the vaccine in the High Court who developed a rare and potentially deadly neurological condition, one of whom died, which imply the vaccine was “defective”.

AstraZeneca faces lawsuits in High Court over ‘defective' Covid-19 vaccine

The headline numbers for Astrazeneca (AZN) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Astrazeneca (AZN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

AstraZeneca has struck a licensing deal worth up to $2 billion for a weight-loss drug. Stockholders are welcoming the move as its shares have lagged behind peers Eli Lilly and Novo Nordisk.

AstraZeneca Is Getting Into the Weight-Loss Drug Game. The Stock Needs a Boost.

Shares of AZN stock popped Thursday after AstraZeneca said it would spend up to $2.01 billion to license an experimental weight-loss drug from Eccogene.

AstraZeneca Is Making A $2 Billion Bet To Rival Lilly, Novo In Obesity Drugs

The drug is similar to Ozempic, which is commonly used for diabetes and weight loss.

AstraZeneca Paying Up To $2 Billion For Experimental Obesity Pill—As Weight Loss Drug Market Grows

AstraZeneca PLC (LSE:AZN) has upgraded its sales forecast for the year, in the hope that its foray into a semaglutide obesity drug will make up for concerns over its Covid-19 vaccine and bolster sales growth driven by its cancer drug.  The pharmaceuticals group reported a 5% increase in turnover for the year to date to US$33.8 billion, with oncology sales rising by a fifth, but according to analysts took a US$2.9 million knock from a slump in Covid-19 medicine sales.

AstraZeneca: "Take some reassurance” from obesity drug bet

UK drugmaker signs agreement with China's Eccogene to work on an obesity and type 2 diabetes pill

AstraZeneca makes bigger push into weight-loss market with new drug deal

Anglo-Swedish drugmaker AstraZeneca on Thursday upped its earnings forecasts for the year as surging sales of cancer medicines offset plummeting sales of COVID vaccines.

AstraZeneca hikes earnings forecast as surging cancer drug sales offset plunging revenue from COVID vaccines

AstraZeneca moved on Thursday to boost its drugs pipeline in the booming anti-obesity market, saying it would pay China's Eccogene up to about $2 billion for an exclusive licence to develop an experimental oral drug in the field.

AstraZeneca raises stakes in obesity drug race with Eccogene deal

Shares of AstraZeneca PLC (LSE:AZN) rose 2% following the upward revision to its full-year core earnings per share (EPS) and revenue forecasts. The Anglo-Swedish pharma giant now anticipates a low double-digit percentage rise in core EPS, refining its earlier projection from a high single-digit to a low double-digit percentage increase.

AZ shares up 2% after it tweaks FY guidance higher

Drugmaker AstraZeneca raised its annual core profit outlook on Thursday, helped by strong demand for its oncology and rare blood disorder drugs.

AstraZeneca ups annual outlook on strong cancer drugs demand

Flutter Entertainment PLC

A quarterly update from AstraZeneca PLC (LSE:AZN) approaches with its shares having slipped 15% from the all-time highs reached in the spring, when it jostled back past Shell to regain top spot of the FTSE 100

AstraZeneca, Wizz Air, Flutter: Thursday's highlights

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca (AZN) is leveraging its global industrial-scale manufacturing and digital capabilities to boost US renewable natural gas (RNG) productivity through a planned expanded collaboration with Vanguard Renewables. With an ambition of achieving a multiple fold increase in productivity, the collaboration aims to accelerate parity with fossil fuel-generated natural gas. Drawing on AstraZeneca's global manufacturing, supply chain, digital and scientific exper.

AstraZeneca to leverage its global industrial-scale manufacturing and digital capabilities to boost US renewable natural gas productivity

Amcor Plc

British American Tobacco

Diageo

Legal & General Group PLC

LyondellBasell Industries

Reckitt Benckiser Group PLC

Smith & Nephew

Unilever

For weeks, I have pounded the table about the historic opportunity in REITs. The fundamentals were clear that now was the best time in 14 years to buy REITs. Last week, stocks ripped 6% higher, and REITs soared 9%, powered by falling rates that were the only reason REITs had fallen. Today, there is another Warren Buffett-style "fat pitch" opportunity staring at you in plain sight. UK Stocks are trading at 10X earnings and 7X cash-adjusted earnings, a 30% historical discount.

9 Once-In-A Lifetime Blue-Chip Opportunities Yielding As Much As 10%

Compugen

Rilvegostomig, AstraZeneca's (LSE/STO/Nasdaq: AZN) PD-1/TIGIT bi-specific derived from Compugen's COM902, has progressed into Phase 3 as adjuvant therapy for biliary tract cancer after resection in combination with chemotherapy Clinical data presented at SITC 2023 reinforces COM701 (anti-PVRIG) mediated anti-tumor activity in tumors typically not responding to immunotherapy and initial data suggest PVRL2 as a potential biomarker for COM701 combinations in certain indications Enrollment completed in proof-of-concept study evaluating triple blockade of DNAM-1 axis with COM701 + COM902 (anti-TIGIT) + pembrolizumab in patients with metastatic microsatellite stable colorectal cancer Pre-clinical data presented at SITC 2023 highlights COM503's potential leading edge with an antibody approach to harness IL-18 cytokine biology to treat cancer HOLON, Israel , Nov. 7, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced financial results for the third quarter ended September 30, 2023, and provided a corporate update.

Compugen Reports Third Quarter 2023 Results

Besides Wall Street's top -and-bottom-line estimates for Astrazeneca (AZN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2023.

Unlocking Q3 Potential of Astrazeneca (AZN): Exploring Wall Street Estimates for Key Metrics

Apple

Costco

Chevron

Lockheed Martin

Newmont Mining

Tesla

This column focuses on stocks to buy for long-term wealth creation with evergreen ideas. A key factor that separates evergreen businesses from others is necessity versus luxury.

7 Evergreen Stocks for Long-term Wealth Generation

Persimmon PLC

The FTSE 100 index had a strong performance this week as investors reacted to important UK earnings and the Federal Reserve and Bank of England (BoE) decisions. Some of the top earnings came from oil giants like BP and Shell.

FTSE 100 analysis ahead of Beazley, Flutter, Persimmon, AstraZeneca earnings

AstraZeneca PLC (LSE:AZN) approaches its third-quarter update with its shares having slipped 15% from the all-time highs reached in the spring, when it jostled back past Shell to regain top spot of the FTSE 100.  But the Anglo-Swedish pharma giant has been dented by a steady waning of investor support in recent weeks.

AstraZeneca results offer chance to set itself apart from rivals after FTSE 100 crown slips

CHELMSFORD, Mass.--(BUSINESS WIRE)--AstraZeneca, a global science-led biopharmaceutical company, and Axis Communications, today announced new surveillance upgrades to AstraZeneca's research and development (R&D) center in Gaithersburg, Maryland to not only improve campus security and lab safety, but also enhance operational efficiency and augment sustainability efforts. As one of four global R&D centers, AstraZeneca's Gaithersburg campus – located outside of Washington, DC – is home to.

AstraZeneca Partners With Axis Communications to Improve Security and Enhance Operational Efficiency at Maryland R&D Facility

Cellectis SA

The U.S.-listed shares of Cellectis S.A. CLLS rocketed 179.3% on very heavy volume in premarket trading Wednesday, after the France-based biotechnology company announced an equity investment of $220 million from AstraZeneca PLC AZN as part of a collaboration agreement that leverages Cellectis' gene editing technologies.

Cellectis' stock is the biggest gainer and most active premarket after equity investment, collaboration pact with AstraZeneca

AstraZeneca PLC (LSE:AZN) has entered into a partnership and investment deal with French gene editing specialist biotech firm Cellectis (NASDAQ:CLLS) which it hopes will speed up the development of new treatments in areas such as cancer, immunology, and rare diseases. The headline value of the deal is a comparatively modest (by pharma standards) $105 million.

AstraZeneca inks gene editing deal that could end up costing it $2.5bn

AstraZeneca said on Wednesday it had entered into a collaboration and investment agreement with clinical-stage biotechnology company Cellectis to speed up the development of therapeutics in areas including oncology and rare diseases.

News for AstraZeneca Stock (AZN)